Glucosamine inhibits epithelial-to-mesenchymal transition and migration of retinal pigment epithelium cells in culture and morphologic changes in a mouse model of proliferative vitreoretinopathy

Acta Ophthalmologica

Volumn 89, Issue 6, 2011, Pages

  Liang, Chang Min ^a,b   Tai, Ming Cheng ^b   Chang, Yun Hsiang ^b   Chen, Yi Hao ^b   Chen, Ching Long ^b   Lu, Da Wen ^b   Chen, Jiann Torng ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

epithelial to mesenchymal transition; glucosamine; migration; proliferative vitreoretinopathy; SMAD; transforming growth factor

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR; GLUCOSAMINE; PLATELET DERIVED GROWTH FACTOR; PROTEIN ZO1; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; VITREORETINOPATHY; WOUND CLOSURE;

ACTINS; ANIMALS; BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; COLLAGEN; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL-MESENCHYMAL TRANSITION; GLUCOSAMINE; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MICE; PHOSPHOPROTEINS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RETINAL PIGMENT EPITHELIUM; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; VITREORETINOPATHY, PROLIFERATIVE;

EID: 80052078247     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02147.x     Document Type: Article

References (35)

1. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, &, Aylward GW, (2001): Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology 108: 1179-1183. (Pubitemid 32568123)
2. Baudouin C, Fredj-Reygrobellet D, Brignole F, Negre F, Lapalus P, &, Gastaud P, (1993): Growth factors in vitreous and subretinal fluid cells from patients with proliferative vitreoretinopathy. Ophthalmic Res 25: 52-59. (Pubitemid 23078549)
3. Cassidy L, Barry P, Shaw C, Duffy J, &, Kennedy S, (1998): Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders. Br J Ophthalmol 82: 181-185. (Pubitemid 28176995)
4. Chang YH, Horng CT, Chen YH, Chen PL, Chen CL, Liang CM, Chien MW, &, Chen JT, (2008): Inhibitory effects of glucosamine on endotoxin-induced uveitis in Lewis rats. Invest Ophthalmol Vis Sci 49: 5441-5449.
5. Charteris DG, (1995): Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol 79: 953-960.
6. Charteris DG, Sethi CS, Lewis GP, &, Fisher SK, (2002): Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye 16: 369-374. (Pubitemid 34845964)
7. Choudhury P, Chen W, &, Hunt R, (1997): Production of platelet-derived growth factor by interleukin-1 beta and transforming growth factor-beta-stimulated retinal pigment epithelial cells leads to contraction of collagen gels. Invest Ophthalmol Vis Sci 38: 824-833. (Pubitemid 27193507)
8. Committee TRST (1983): The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90: 121-125.
9. Connor TB Jr, Roberts AB, Sporn MB, et al., (1989): Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest 83: 1661-1666. (Pubitemid 19124123)
10. Eibl KH, Kook D, Priglinger S, Haritoglou C, Yu A, Kampik A, &, Welge-Lussen U, (2006): Inhibition of human retinal pigment epithelial cell attachment, spreading, and migration by alkylphosphocholines. Invest Ophthalmol Vis Sci 47: 364-370. (Pubitemid 46780837)
11. Esser P, Tervooren D, Heimann K, Kociok N, Bartz-Schmidt KU, Walter P, &, Weller M, (1998): Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 39: 164-170. (Pubitemid 28040475)
12. Fan JM, Ng YY, Hill PA, Nikolic-Paterson DJ, Mu W, Atkins RC, &, Lan HY, (1999): Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 56: 1455-1467. (Pubitemid 29451252)
13. He PM, He S, Garner JA, Ryan SJ, &, Hinton DR, (1998): Retinal pigment epithelial cells secrete and respond to hepatocyte growth factor. Biochem Biophys Res Commun 249: 253-257. (Pubitemid 28418729)
14. He S, Chen Y, Khankan R, et al., (2008): Connective tissue growth factor as a mediator of intraocular fibrosis. Invest Ophthalmol Vis Sci 49: 4078-4088.
15. Hinton DR, He S, Jin ML, Barron E, &, Ryan SJ, (2002): Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye 16: 422-428. (Pubitemid 34845970)
16. Kalluri R, &, Neilson EG, (2003): Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784. (Pubitemid 38063698)
17. Kirchhof B, (2004): Strategies to influence PVR development. Graefes Arch Clin Exp Ophthalmol 242: 699-703. (Pubitemid 39242847)
18. Koch HU, Schwarz RT, &, Scholtissek C, (1979): Glucosamine itself mediates reversible inhibition of protein glycosylation. A study of glucosamine metabolism at inhibitory concentrations in influenza-virus-infected cells. Eur J Biochem 94: 515-522. (Pubitemid 9236101)
19. Kon CH, Occleston NL, Aylward GW, &, Khaw PT, (1999): Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 40: 705-712. (Pubitemid 29109449)
20. Leask A, Holmes A, Black CM, &, Abraham DJ, (2003): Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem 278: 13008-13015. (Pubitemid 36800068)
21. Lee H, O'Meara SJ, O'Brien C, &, Kane R, (2007): The role of gremlin, a BMP antagonist, and epithelial-to-mesenchymal transition in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 48: 4291-4299. (Pubitemid 351261061)
22. Liang CM, Tai MC, Chang YH, Chen YH, Chen CL, Chien MW, &, Chen JT, (2010): Glucosamine inhibits epidermal growth factor-induced proliferation and cell-cycle progression in retinal pigment epithelial cells. Mol Vis 16: 2559-2571.
23. Machemer R, (1988): Proliferative vitreoretinopathy (PVR): a personal account of its pathogenesis and treatment. Proctor lecture. Invest Ophthalmol Vis Sci 29: 1771-1783.
24. Mazure A, &, Grierson I, (1992): In vitro studies of the contractility of cell types involved in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 33: 3407-3416.
25. Okada H, Danoff TM, Kalluri R, &, Neilson EG, (1997): Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 273: 563-574.
26. Pan Y, &, Elbein A, (1982): The formation of lipid-linked oligosaccharides in Madin-Darby canine kidney cells. Changes in oligosaccharide profiles induced by glucosamine. J Biol Chem 257: 2795-2801. (Pubitemid 12118797)
27. Partridge EA, Le Roy C, Di Guglielmo GM, et al., (2004): Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306: 120-124. (Pubitemid 39451953)
28. Pastor JC, (1998): Proliferative vitreoretinopathy: an overview. Surv Ophthalmol 43: 3-18. (Pubitemid 28364465)
29. Pratt CH, Vadigepalli R, Chakravarthula P, Gonye GE, Philp NJ, &, Grunwald GB, (2008): Transcriptional regulatory network analysis during epithelial-mesenchymal transformation of retinal pigment epithelium. Mol Vis 14: 1414-1428.
30. Saika S, Kono-Saika S, Tanaka T, et al., (2004): Smad3 is required for dedifferentiation of retinal pigment epithelium following retinal detachment in mice. Lab Invest 84: 1245-1258. (Pubitemid 40063691)
31. Saika S, Yamanaka O, Nishikawa-Ishida I, et al., (2007): Effect of Smad7 gene overexpression on transforming growth factor beta-induced retinal pigment fibrosis in a proliferative vitreoretinopathy mouse model. Arch Ophthalmol 125: 647-654. (Pubitemid 46762726)
32. Saika S, Yamanaka O, Okada Y, et al., (2009): TGF beta in fibroproliferative diseases in the eye. Front Biosci (Schol Ed) 1: 376-390.
33. Scheer S, Morel C, Touzeau O, Sahel JA, &, Laroche L, (2004): [Pharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy]. J Fr Ophtalmol 27: 1051-1059. (Pubitemid 39556836)
34. Takahashi M, Tsuda T, Ikeda Y, Honke K, &, Taniguchi N, (2004): Role of N-glycans in growth factor signaling. Glycoconj J 20: 207-212.
35. Yang CS, Khawly JA, Hainsworth DP, Chen SN, Ashton P, Guo H, &, Jaffe GJ, (1998): An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 116: 69-77. (Pubitemid 28098896)